Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766035 · ClinicalTrials.gov registry record
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 43
- Enrollment target
NCT03766035 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 43 participants.
The verdict
NCT03766035 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
Interventions
- DEVICE SpyGlass DS I - II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2022-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03766035
The ClinicalTrials.gov registry entry for NCT03766035 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SpyGlass DS I - II is the first listed.
NCT03766035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03766035 about?
NCT03766035 is a clinical study titled "Cholangioscopy in Primary Sclerosing Cholangitis (PSC)". To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT03766035?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2018-12-06. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT03766035?
The interventions under investigation include: SpyGlass DS I - II (DEVICE).
Who is sponsoring clinical trial NCT03766035?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.